The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...

But researchers are enamored with the pointy-face shrew for another one of its natural talents: It vomits. That makes the ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching emerging channels and artificial ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Now the Danish company is hoping to score a similar nod for its under-the-radar oral version of GLP-1 treatment. The FDA has accepted Novo’s application for a label extension for Rybelsus to reduce ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 ...